Citations

Clear

1434 citation(s) found for "Uk, Nathan".

LCK and resistance to cytotoxic chemotherapy via activating an AXL-PEAK1 signaling axis in cholangiocarcinoma.
Takaichi, Shohei , Yu, Mincheng, Tomlinson, Jennifer L. , Carlson, Danielle M. , Werneburg, Nathan W., Wu, Xinyan , Smoot, Rory L. , Smoot, Rory L , Tomlinson, Jennifer , Mun, Dong‐Gi , Abdelrahman, Amro M. , Carlson, Danielle Marie , Pandey, Akhilesh , Gores, Gregory J.

Mayo Clinic

JCO Global Oncology | August 3, 2023 | Volume: 9 | Issue: Supplement_1 | Pages: 27-27

10.1200/go.2023.9.supplement_1.27 Get It

27 Background: Cholangiocarcinoma (CCA) is a devastating cancer with few effective treatment options. We have previously discovered LCK can activate AXL, a TAM receptor tyrosine kinase (RTK), by phosphorylation of AXL-Y866 ( J Hepatol 2022). AXL is known to confer therapeutic resistance to solid cancers. However, the role of AXL in CCA, and the impact of AXL-Y866 activation by LCK still remains to be elucidated. Here, we investigated the significance of AXL expression, signaling, and activation by LCK on Y866. Methods: We first evaluated the expression levels of AXL in CCA and its association with patient outcome using The Cancer Genome Atlas (TCGA) dataset. Next, to evaluate whether AXL inactivation sensitizes CCA cells to gemcitabine and cisplatin (GC), AXL downregulation was achieved via siRNA approach and the selective AXL inhibitor bemcentinib (Bem) using human CCA cell lines, HuCCT1 and RBE, and murine SB-1. We examined 50% inhibitory concentration (IC50) value on GC with or without AXL knockdown (KD) using cell viability assay. Then we assessed the efficacy of the combination of GC and Bem utilizing Calcusyn software and apoptosis by Annexin V assay. I n vivo efficacy was assessed using both a patient derived CCA xenograft and SB-1 a syngeneic model of CCA treated with vehicle, GC, Bem, or the combination. Next, we defined the interactome of wildtype AXL- Y866 compared to AXL-Y866F using biotin proximity labelling methods (BioID), validation of downstream target proteins using Western blot (WB), and a functional study with AXL-/- cells reconstituted with either AXL WT, or AXL Y866F. Results: In TCGA cohorts, AXL transcripts are more abundant than in normal adjacent liver, and higher levels are correlated with worse clinical outcome. In in vitro study, IC50 values of GC decreased after AXL KD. Synergistic effects were observed in the combination. The combination caused increased apoptosis compared to other treatments. In the in vivo studies, the combination suppressed tumor growth and the Ki67 levels, and the phosphorylation levels of PEAK1 decreased in the combination group compared to other groups. In BioID experiments, among the 222 proteins which were detected in both AXL WT and AXL Y866F interactomes, PEAK1 kinase, which localizes to actin cytoskeleton and focal adhesions, was most altered when Y866 was inactivated by the Y866F mutation. In gene ontology analysis, cell-cell adhesion and focal adhesion related proteins were enriched. In WB, we validated that the phosphorylation of PEAK1 decreased after AXL or LCK knockout (KO) and after Bem treatment in above in vivo study. In cell viability assay, reconstitution of AXL KO cells with WT AXL increased the IC50 to GC while reconstitution with AXL-Y866F did not. Conclusions: AXL inhibition sensitizes CCA cells to cytotoxic chemotherapy in preclinical model. LCK-AXL Y866-PEAK1 signaling axis is a potential target for the treatment of CCA.
Advancing specificity in delirium: The delirium subtyping initiative
Bowman, Emily M L , Fiest, Kirsten M. , Girard, Timothy D. , Jackson, Thomas , LaHue, Sara C. , MacLullich, Alasdair M. J. , McAuley, Daniel F. , Potter, Kelly , Sinha, Pratik , Slooter, Arjen J. C. , Sweeney, Aoife , Tieges, Zoë , Dellen, Edwin van , Wilcox, M. Elizabeth , Cunningham, Emma , Lindroth, Heidi L., Girard, Timothy D , MacLullich, Alasdair M J , Slooter, Arjen J C , Brummel, Nathan E. , Caplan, Gideon A. , Cunningham, Colm M. , Evered, Lisbeth Anne , Lindroth, Heidi , Oh, Esther S , Oldham, Mark , Page, Valérie , Pandharipande, Pratik , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | July 31, 2023 | Volume: 20 | Issue: 1 | Pages: 183-194

10.1002/alz.13419 | PMID 37522255 Get It

AbstractBACKGROUNDDelirium, a common syndrome with heterogeneous etiologies and clinical presentations, is associated with poor long‐term outcomes. Recording and analyzing all delirium equally could be hindering the field's understanding of pathophysiology and identification of targeted treatments. Current delirium subtyping methods reflect clinically evident features but likely do not account for underlying biology.METHODSThe Delirium Subtyping Initiative (DSI) held three sessions with an international panel of 25 experts.RESULTSMeeting participants suggest further characterization of delirium features to complement the existing Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revision diagnostic criteria. These should span the range of delirium‐spectrum syndromes and be measured consistently across studies. Clinical features should be recorded in conjunction with biospecimen collection, where feasible, in a standardized way, to determine temporal associations of biology coincident with clinical fluctuations.DISCUSSIONThe DSI made recommendations spanning the breadth of delirium research including clinical features, study planning, data collection, and data analysis for characterization of candidate delirium subtypes.Highlights Delirium features must be clearly defined, standardized, and operationalized. Large datasets incorporating both clinical and biomarker variables should be analyzed together. Delirium screening should incorporate communication and reasoning.
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
Paiva, Bruno , Manrique, Irene , Campbell, Timothy , Kazanecki, Christian C. , Martin, Nathan , Anderson, Larry D. , Berdeja, Jesús G. , Lonial, Sagar , Raje, Noopur , Munshi, Nikhil C. , Kaiser, Shari M. , Rytlewski, Julie , Campbell, Timothy , Kazanecki, Christian C , Martin, Nathan , Anderson, Larry D , Berdeja, Jesús G , Lonial, Sagar , Raje, Noopur S , Lin, Yi , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C , Kaiser, Shari M , Paiva, Bruno , Lin, Yi , Moreau, Philippe , Miguel, Jesús F. San

Mayo Clinic

Blood Cancer Discovery | July 24, 2023 | Volume: 4 | Issue: 5 | Pages: 365-373

10.1158/2643-3230.bcd-23-0044 | PMID 37486974 Get It

Abstract The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10−6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality. Significance: This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337
76. Measuring the Effect of Glabellar Paralysis on Facial Expression of Emotion Using an Artificial Intelligence Application
Hebel, Nathan , Boonipat, Thanapoom , Stotland, Mitchell A.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 21, 2023 | Volume: 11 | Issue: 5S | Pages: 47-48

10.1097/01.gox.0000937896.63554.b7 Get It

“An unusual case of diffuse cystic lung disease: A teenager with lung metastasis”
Guler, Sevim , NC, Hull, Arteta, Manuel , Demirel, Nadir , Guler, Sevim , Hull, Nathan C.

Mayo Clinic

No container title available | July 17, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.168963127.72176788/v1 Get It

We are presenting a teenage girl with a recent history of virilism who presented with tension pneumothorax. Subsequent contrast-enhanced chest CT revealed multiple bilateral irregular thin-walled cysts of varying sizes with numerous solid noncalcified pulmonary nodules and pulmonary artery pseudoaneurysms. Lung biopsy revealed trophoblastic neoplasm with metastasis to both lungs. We discussed the differential diagnosis of diffuse cystic lung diseases. While diffuse cystic lung diseases in children are rarely due to malignancy, we emphasize that clinicians be aware of the possibility of metastatic lung diseases and their radiologic features when encountering diffuse cystic lung diseases.
Mechanomyography as a Surgical Adjunct for Treatment of Chronic Entrapment Neuropathy: A Case Series
Javeed, Saad , Birenbaum, Nathan , Dibble, Christopher F., Benedict, Braeden , Sydnor, Kiersten , Faraji, Amir H. , Spinner, Robert J. , Ray, Wilson Z. , Xu, Yameng , Greenberg, Jacob K , Zhang, Justin K. , Dy, Christopher J. , Brogan, David M.

Mayo Clinic

Operative Neurosurgery | July 13, 2023 | Volume: 25 | Issue: 3 | Pages: 242-250

10.1227/ons.0000000000000812 | PMID 37441801 Get It

BACKGROUND: Chronic entrapment neuropathy results in a clinical syndrome ranging from mild pain to debilitating atrophy. There remains a lack of objective metrics that quantify nerve dysfunction and guide surgical decision-making. Mechanomyography (MMG) reflects mechanical motor activity after stimulation of neuromuscular tissue and may indicate underlying nerve dysfunction. OBJECTIVE: To evaluate the role of MMG as a surgical adjunct in treating chronic entrapment neuropathies. METHODS: Patients 18 years or older with cubital tunnel syndrome (n = 8) and common peroneal neuropathy (n = 15) were enrolled. Surgical decompression of entrapped nerves was performed with intraoperative MMG of the hypothenar and tibialis anterior muscles. MMG stimulus thresholds (MMG-st) were correlated with compound muscle action potential (CMAP), motor nerve conduction velocity, baseline functional status, and clinical outcomes. RESULTS: After nerve decompression, MMG-st significantly reduced, the mean reduction of 0.5 mA (95% CI: 0.3-0.7, P < .001). On bivariate analysis, MMG-st exhibited significant negative correlation with common peroneal nerve CMAP ( P < .05), but no association with ulnar nerve CMAP and motor nerve conduction velocity. On preoperative electrodiagnosis, 60% of nerves had axonal loss and 40% had conduction block. The MMG-st was higher in the nerves with axonal loss as compared with the nerves with conduction block. MMG-st was negatively correlated with preoperative hand strength (grip/pinch) and foot-dorsiflexion/toe-extension strength ( P < .05). At the final visit, MMG-st significantly correlated with pain, PROMIS-10 physical function, and Oswestry Disability Index ( P < .05). CONCLUSION: MMG-st may serve as a surgical adjunct indicating axonal integrity in chronic entrapment neuropathies which may aid in clinical decision-making and prognostication of functional outcomes.
Predictive power of chest radiography for infectious or inflammatory lung disease
Hull, Nate C., Thacker, Paul G. , Boesch, R. Paul , Boesch, Richard P , Hull, Nathan C.

Mayo Clinic

Pediatric Pulmonology | July 11, 2023 | Volume: 58 | Issue: 10 | Pages: 2804-2808

10.1002/ppul.26591 | PMID 37431956 Get It

AbstractObjectiveChildren frequently present with chronic cough, recurrent respiratory infections, and dysphagia. These symptoms are poor predictors of significant inflammatory lung disease, such as from chronic aspiration. Bronchoalveolar lavage (BAL) is the gold standard for identification of lung infection and airway inflammation but is expensive and requires sedation. Chest X‐rays (CXR) are inexpensive, low‐radiation tests that do not require sedations and can document findings associated with infectious or inflammatory lung disease. The accuracy of CXR to predict or exclude infectious or inflammatory lung disease has not been directly evaluated and is unknown.MethodsRetrospective cohort of all pediatric patients who underwent FFB with BAL within 2 weeks of a CXR. Blinded CXR images reviewed for findings consistent with inflammatory disease by two senior pediatric radiologists. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for CXR to identify significant inflammation and/or infection on BAL were calculated.ResultsThree hundred and forty‐four subjects included. Two hundred and sixty‐three had positive CXR (77%), 183 had inflammatory BAL (53%), and 110 had infection (32%). The sensitivity of CXR changes for BAL inflammation, infection, and either inflammation or infection was 84.7, 90.9, and 85.3, respectively. The PPV of CXR was 58.9, 38.0, and 59.7. The NPV of CXR was 65.0, 87.5, and 66.3.ConclusionsAlthough CXR are inexpensive, do not require sedation, and are of low radiation dose, the ability of an entirely normal CXR to exclude active inflammatory or infectious lung disease is limited.
A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
Rades, Dirk , Zwaan, Inga, Idel, Christian, Pries, Ralph , BRUCHHAGE, KARL L., Hakim, Samer G. , Yu, Nathan Y. , Soror, Tamer

Mayo Clinic

Journal of Personalized Medicine | July 11, 2023 | Volume: 13 | Issue: 7 | Pages: 1120

10.3390/jpm13071120 | PMID 37511733 Get It

Many head and neck cancer patients assigned to definitive or adjuvant chemoradiation treatment do not complete the concurrent cisplatin dose. We determined corresponding risk factors and developed a prognostic instrument to help identify these patients. Ten pre-treatment characteristics were retrospectively analyzed in 154 patients with head and neck cancer who were treated via chemoradiation with cisplatin. These pre-treatment characteristics included age, sex, Karnofsky performance score, tumor site, primary tumor stage, nodal stage, histologic grade, upfront surgery, human papilloma virus status, and history of smoking. The characteristics significantly associated with the completion of cisplatin-based treatment, the receipt of ≥80% cisplatin, or showing a strong trend of association after multivariate analyses were used for the prognostic instrument. For each characteristic, 0 points were assigned for worse outcomes, and 1 point was assigned for better outcomes. Patients’ scores were calculated by adding these points. Age ≤ 60 years and a Karnofsky performance score of 90–100 were significantly associated with both endpoints after multivariate analysis, and male gender showed a trend for association with the receipt of ≥80% cisplatin. Patient scores were 0, 1, 2, and 3 points. The corresponding rates of completion of cisplatin-based treatment were 14%, 41%, 62%, and 72%, respectively (p = 0.004). The rates of receipt of ≥80% cisplatin were 29%, 54%, 72%, and 94%, respectively (p < 0.001). This new prognostic instrument helps to predict whether head and neck cancer patients scheduled for chemoradiation will receive cisplatin as planned.
Role of individual factor X concentrate pharmacokinetic studies in perioperative management of AL amyloidosis‐associated acquired factor X deficiency
Lewis, Akeem R. , Peffley, Nathan, Klompas, Allan M. , Ashrani, Aneel A.

Mayo Clinic

Transfusion | July 10, 2023 | Volume: 63 | Issue: 9 | Pages: 1773-1777

10.1111/trf.17477 | PMID 37427705 Get It

AbstractBackgroundAL amyloidosis is associated with acquired factor X (FX) deficiency. Experience related to its management is limited to case reports and series using prothrombin complex concentrate, fresh frozen plasma, plasma exchange, recombinant activated factor seven, and desmopressin with limited and variable efficacy. FX concentrate has not been widely used in its management.Study Design and MethodsWe report our experience with the perioperative use of FX concentrate (Coagadex) in two patients with AL amyloidosis‐associated acquired FX deficiency requiring surgery, using their individual pharmacokinetic studies to manage perioperative hemostasis. Pharmacokinetic studies involved obtaining post‐infusion FX activity at 10 min, 2, and 4 h following the administration of FX concentrate to calculate the FX half‐life.ResultsBoth patients' plasma FX activity was successfully increased to provide perioperative hemostatic support. Monitoring FX activity post‐surgery was also utilized to maintain FX activity levels to prevent post‐operative bleeding.ConclusionPharmacokinetic studies have a useful role in tailoring preoperative FX repletion in patients with AL amyloidosis associated with acquired FX deficiency.
Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real‐world patient data repository
Farber, Harrison W. , Chakinala, Murali M. , Cho, Michelle, Frantz, Robert P. , Frick, Andrew , Lancaster, Lisa , Milligan, Scott , Oudiz, Ronald J. , Panjabi, Sumeet , Tsang, Yuen, Nathan, Steven D. , Frantz, Robert P , Oudiz, Ronald

Mayo Clinic

Pulmonary Circulation | July 7, 2023 | Volume: 13 | Issue: 3 | Pages: No page available

10.1002/pul2.12258 | PMID 37427090 Get It

AbstractPulmonary arterial hypertension (PAH) is a rare, life‐limiting disease. PAH registries provide real‐world data that complement clinical trial data and inform treatment decisions. The TRIO comprehensive, integrated patient data repository (TRIO CIPDR), is an innovative US repository capturing data on contemporary patients diagnosed with pulmonary hypertension and receiving US Food and Drug Administration‐approved PAH therapies. This repository uniquely combines clinical data from electronic medical records with the ability to track drug‐prescription and drug‐dispensing characteristics, and includes 946 adult patients with PAH (data collected January 2019 to December 2020) enrolled from nine representative US specialist tertiary care centers. Potentially eligible patients were identified based on dispensing data from specialty pharmacies. Hemodynamic and clinical data, as well as dispensing information on prescribed PAH medications, were provided by tertiary centers. At enrollment, 75% of patients were female, 67% were White, median age at PAH diagnosis was 53 years (median time from diagnosis to enrollment was 5 years), and 37% were obese. Comorbidity profiles were as expected for a PAH population, although the proportion with atrial fibrillation (34%) was higher than expected. Overall, 38% of patients had idiopathic PAH and 30% had connective tissue disease‐related PAH. Among 917 patients receiving PAH‐specific therapy, 40% were on monotherapy, 43% on dual therapy, and 17% on triple therapy. Longitudinal data from this repository will allow tracking of the PAH treatment journey in relation to clinical characteristics and outcomes.